Ceapro Bolsters Executive Management Team with Appointment of Sigrun Watson as Chief Revenue Officer
July 12 2022 - 8:35AM
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF)
(“Ceapro” or the “Company”), a growth-stage biotechnology
company focused on the development and commercialization of active
ingredients for healthcare and cosmetic industries, today announced
the appointment of Sigrun Watson as its Chief Revenue Officer,
responsible for corporate strategy development and execution across
the Cosmeceutical and personal care brand business, as well as
Ceapro’s expansion into the Nutraceutical and Pharmaceutical
markets.
Ms. Watson is an accomplished and strategic
commercial leader with over 20 years of diverse healthcare
management experience spanning a broad spectrum of products
(pharmaceuticals, biologics, diagnostics/genetic testing, medical
devices, and nutritional products), across multiple commercial
channels, including specialty pharmaceuticals, biologics, primary
care, institutional contract selling, direct to consumer/digital
marketing, retail accounts, and business to business account
development.
Gilles Gagnon, President and Chief Executive
Officer of Ceapro commented, “We are incredibly pleased to welcome
Sigrun to the Ceapro management team. It is a pivotal moment for
the Company as we continue expand our business model into
nutraceuticals and pharmaceuticals, and her background as a
Registered Dietitian/Nutritionist and extensive experience in
pharma are extremely relevant. We look forward to leveraging her
knowledge and expertise as we execute on our initiatives moving
forward to propel Ceapro to its next phase of growth.”
With extensive experience leading and developing
high performing teams, as well as managing and growing healthcare
brands and portfolios across product lifecycles, including numerous
product launches/line extensions spanning multiple therapeutic
areas, Ms. Watson has consistently been recognized for her
leadership, strategic planning, launch planning and execution, and
business development/key account management.
Prior to joining Ceapro, Ms. Watson served as
Vice President of Marketing and Sales at Inagene Diagnostics Inc.,
a global genetic testing and precision medicine company, where she
led the development and execution of the commercialization
strategy, played a pivotal role in building the product offering,
company and cross-functional team from the ground up, and assisted
with fundraising activities. Prior to her role at Inagene, she held
a variety of progressive commercial leadership roles in
pharmaceuticals including marketing, sales management, sales
training, operational excellence, and business development/key
account management with leading pharmaceutical companies including
Eli Lilly, Novartis, Nycomed (now Takeda), GlaxoSmithKline, and
Eisai Pharmaceuticals.
“Ceapro has laid a solid foundation in its
Cosmeceutical business sector and has positioned itself for
significant growth across the Nutraceutical and Pharmaceutical
markets. I couldn’t be more excited to be joining Ceapro at this
pivotal time in the role of Chief Revenue Officer, where I will
have the opportunity to capitalize on the diverse experience I’ve
amassed over the course of my career and make meaningful
contributions to Ceapro’s ongoing success. I look forward to
working closely with the cross-functional team to help realize the
strong pipeline of opportunity and strategic initiatives the
Company has prepared itself to execute on,” added Ms. Watson.
Ms. Watson began her career as a Registered
Dietitian working in business development, and marketing with
Nestle Canada and with Toronto – based healthcare foodservice
company Marsan Foods Ltd, after earning a degree in Nutritional
Sciences (Human Ecology) at the University of Manitoba and
subsequently completing a Dietetic Internship at the Health
Sciences Centre in Winnipeg, Manitoba.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company
involved in the development of proprietary extraction technology
and the application of this technology to the production of
extracts and “active ingredients” from oats and other renewable
plant resources. Ceapro adds further value to its extracts by
supporting their use in cosmeceutical, nutraceutical, and
therapeutics products for humans and animals. The Company has a
broad range of expertise in natural product chemistry,
microbiology, biochemistry, immunology and process engineering.
These skills merge in the fields of active ingredients,
biopharmaceuticals and drug-delivery solutions.
For more information on Ceapro, please visit the
Company’s website at www.ceapro.com.
For more information contact:
Jenene ThomasJTC Team, LLCInvestor Relations and Corporate
Communications AdvisorT (US): +1 (833) 475-8247E: czo@jtcir.com
Issuer:
Gilles R. Gagnon, M.Sc., MBAPresident & CEOT:
780-421-4555
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release
Ceapro (TSXV:CZO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ceapro (TSXV:CZO)
Historical Stock Chart
From Apr 2023 to Apr 2024